Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
+0.53%
SPX
+0.32%
IXIC
+0.25%
FTSE
-0.13%
N225
-0.31%
AXJO
+0.49%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Stocks
0.00 (0.00%)
0.000
USD
At close at --,----
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Join our newsletter to keep up to date with us!

Overview

Loading chart...

Key Stats

Market Cap
8.90B
Dividend Yield
0.00%
P/E Ratio
-545.57
EPS
-2.16
Revenue
42.28M
Avg. Volume
2.48M

About

What does VRNA do?
Verona Pharma Plc develops therapeutics for respiratory diseases, focusing on its investigational inhaled drug, ensifentrine, for chronic obstructive pulmonary disease (COPD). Two additional formulations of ensifentrine are in Phase II development.
Sector
💻 Health Care
IPO
CEO
Employees
Headquarters
United Kingdom
Website
http://www.veronapharma.com
Stocks
Health Care
vrna
Verona Pharma Plc
VRNA
-0.02 (-0.01%)
104.755
USD
At close at Jul 16, 20:42 UTC
Summary
News
Signals
Benchmarks
Financials

Recently from Cashu

publisher logo
Cashu

Verona Pharma Plc Acquired by Merck: A New Era in Respiratory Medicine

4 days ago
publisher logo
Cashu

Merck Acquires Verona Pharma Plc for $10 Billion to Enhance Respiratory Treatment Portfolio

5 days ago
publisher logo
Cashu

Verona Pharma Plc: Leveraging Whale Alert Insights for Strategic Market Navigation

18 days ago